Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer

Prostate

Volumn 68, Issue 6, 2008, Pages 661-674

  Aitchison, Alan A ^a,d   Veerakumarasivam, Abhi ^b   Vias, Maria ^b   Kumar, Rajeev ^c   Hamdy, Freddie C ^c   Neal, David E ^b   Mills, Ian G ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Androgen receptor; Methylation; Smad4

Indexed keywords

ANDROGEN RECEPTOR; SMAD4 PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CHROMOSOME 18; COMPARATIVE GENOMIC HYBRIDIZATION; CORRELATION ANALYSIS; GENE AMPLIFICATION; GENE DELETION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METHYLATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; X CHROMOSOME;

ADENOCARCINOMA; CELL LINE, TUMOR; CHROMOSOMES, ARTIFICIAL, BACTERIAL; CHROMOSOMES, HUMAN, X; DNA METHYLATION; DNA, NEOPLASM; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDES; PROMOTER REGIONS (GENETICS); PROSTATECTOMY; PROSTATIC NEOPLASMS; SMAD4 PROTEIN; TUMOR MARKERS, BIOLOGICAL;

EID: 42949087886     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20730     Document Type: Article

References (37)

1. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000;342(18):1350-1358.
2. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995;268(5215):1336-1338.
3. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271(5247):350-353.
4. Wakefield LM, Roberts AB. TGF-beta signaling: Positive and negative effects on tumorigenesis. Curr Opin Genet Dev 2002;12(1):22-29.
5. Tu WH, Thomas TZ, Masumori N, Bhowmick NA, Gorska AE, Shyr Y, Kasper S, Case T, Roberts RL, Shappell SB, Moses HL, Matusik RJ. The loss of TGF-beta signaling promotes prostate cancer metastasis. Neoplasia 2003;5(3):267-277.
6. Wikstrom P, Westin P, Stattin P, Damber JE, Bergh A. Early castration-induced upregulation of transforming growth factor betal and its receptors is associated with tumor cell apoptosis and a major decline in serum prostate-specific antigen in prostate cancer patients. Prostate 1999;38(4):268-277.
7. Wikstrom P, Bergh A, Damber JE. Transforming growth factor-beta1 and prostate cancer. Scand J Urol Nephrol 2000;34(2):85-94.
8. Wikstrom P, Damber J, Bergh A. Role of transforming growth factor-beta1 in prostate cancer. Microsc Res Tech 2001;52(4):411-419.
9. Derynck R, Zhang Y, Feng XH. Smads: Transcriptional activators of TGF-beta responses. Cell 1998;95(6):737-740.
10. Massague J. TGF-beta signal transduction. Annu Rev Biochem 1998;67:753-791.
11. Wrana JL, Attisano L. MAD-related proteins in TGF-beta signalling. Trends Genet 1996;12(12):493-496.
12. Kang HY, Lin HK, Hu YC, Yeh S, Huang KE, Chang C. From transforming growth factor-beta signaling to androgen action: Identification of Smad3 as an androgen receptor coregulator in prostate cancer cells. Proc Natl Acad Sci USA 2001;98(6):3018-3023.
13. Subramaniam N, Leong GM, Cock TA, Flanagan JL, Fong C, Eisman JA, Kouzmenko AP. Cross-talk between 1,25-dihydroxyvitamin D3 and transforming growth factor-beta signaling requires binding of VDR and Smad3 proteins to their cognate DNA recognition elements. J Biol Chem 2001;276(19):15741-15746.
14. Zhang Y, Feng X, We R, Derynck R. Receptor-associated Mad homologues synergize as effectors of the TGF-beta response. Nature 1996;383(6596):168-172.
15. Zhang Y, Feng XH, Derynck R. Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription. Nature 1998;394(6696):909-913.
16. Takaku K, Oshima M, Miyoshi H, Matsui M, Seldin MF, Taketo MM. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell 1998;92(5):645-656.
17. Dai JL, Bansal RK, Kern SE. G1 cell cycle arrest and apoptosis induction by nuclear Smad4/Dpc4: Phenotypes reversed by a tumorigenic mutation. Proc Natl Acad Sci USA 1999;96(4):1427-1432.
18. Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, Weinstein CL, Bova GS, Isaacs WB, Cairns P, Nawroz H, Sidransky D, Casero RA Jr, Meltzer PS, Hahn SA, Kern SE. DPC4 gene in various tumor types. Cancer Res 1996;56(11):2527-2530.
19. MacGrogan D, Pegram M, Slamon D, Bookstein R. Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas. Oncogene 1997;15(9):1111-1114.
20. Brodin G, ten Dijke P, Funa K, Heldin CH, Landstrom M. Increased smad expression and activation are associated with apoptosis in normal and malignant prostate after castration. Cancer Res 1999;59(11):2731-2738.
21. Rao CN, Segawa T, Navari JR, Xu L, Srivastava S, Moul JW, Phillips B. Methylation of TFPI-2 gene is not the sole cause of its silencing. Int J Oncol 2003;22(4):843-848.
22. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93(18):9821-9826.
23. Fiegler H, Carr P, Douglas EJ, Burford DC, Hunt S, Scott CE, Smith J, Vetrie D, Gorman P, Tomlinson IP, Carter NP. DNA microarrays for comparative genomic hybridization based on DOP-PCR amplification of BAC and PAC clones. Genes Chromosomes Cancer 2003;36(4):361-374.
24. Roth S, Laiho P, Salovaara R, Launonen V, Aaltonen LA. No SMAD4 hypermethylation in colorectal cancer. Br J Cancer 2000;83(8):1015-1019.
25. Zhoul J, Hernandez G, Tu SW, Huang CL, Tseng CP, Hsieh JT. The role of DOC-2/DAB2 in modulating androgen receptor-mediated cell growth via the nongenomic c-Src-mediated pathway in normal prostatic epithelium and cancer. Cancer Res 2005;65(21):9906-9913.
26. Yano M, Toyooka S, Tsukuda K, Dote H, Ouchida M, Hanabata T, Aoe M, Date H, Gazdar AF, Shimizu N. Aberrant promoter methylation of human DAB2 interactive protein (hDAB2IP) gene in lung cancers. Int J Cancer 2005;113(1):59-66.
27. Chen H, Pong RC, Wang Z, Hsieh JT. Differential regulation of the human gene DAB2IP in normal and malignant prostatic epithelia: Cloning and characterization. Genomics 2002;79(4):573-581.
28. Dote H, Toyooka S, Tsukuda K, Yano M, Ouchida M, Doihara H, Suzuki M, Chen H, Hsieh JT, Gazdar AF, Shimizu N. Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer. Clin Cancer Res 2004;10(6):2082-2089.
29. Wicker N, Carles A, Mills IG, Wolf M, Veerakumarasivam A, Edgren H, Boileau F, Wasylyk B, Schalken JA, Neal DE, Kallioniemi O, Poch O. A new look towards BAC-based array CGH through a comprehensive comparison with oligo-based array CGH. BMC Genomics 2007;8:84.
30. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995;9(4):401-406.
31. Gaasenbeek M, Howarth K, Rowan AJ, Gorman PA, Jones A, Chaplin T, Liu Y, Bicknell D, Davison EJ, Fiegler H, Carter NP, Roylance RR, Tomlinson IP. Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex changes and multiple forms of chromosomal instability in colorectal cancers. Cancer Res 2006;66(7):3471-3479.
32. Onwuegbusi BA, Aitchison A, Chin SF, Kranjac T, Mills I, Huang Y, Lao-Sirieix P, Caldas C, Fitzgerald RC. Impaired transforming growth factor beta signalling in Barrett's carcinogenesis due to frequent SMAD4 inactivation. Gut 2006;55(6):764-774.
33. Harden SV, Sanderson H, Goodman SN, Partin AA, Walsh PC, Epstein JI, Sidransky D. Quantitative GSTP1 methylation and the detection of prostate adenocarcinoma in sextant biopsies. J Natl Cancer Inst 2003;95(21):1634-1637.
34. Hadzija MP, Radosevic S, Kovacevic D, Lukac J, Hadzija M, Spaventi R, Pavelic K, Kapitanovic S. Status of the DPC4 tumor suppressor gene in sporadic colon adenocarcinoma of Croatian patients: Identification of a novel somatic mutation. Mutat Res 2004;548(1-2):61-73.
35. Sunamura M, Lefter LP, Duda DG, Morita R, Inoue H, Yokoyama T, Yatsuoka T, Abe T, Egawa S, Furukawa T, Fukushige S, Oshimura M, Horii A, Matsuno S. The role of chromosome 18 abnormalities in the progression of pancreatic adenocarcinoma. Pancreas 2004;28(3):311-316.
36. Wilentz RE, Iacobuzio-Donahue CA, Argani P, McCarthy DM, Parsons JL, Yeo CJ, Kern SE, Hruban RH. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: Evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000;60(7):2002-2006.
37. Peter BJ, Kent HM, Mills IG, Vallis Y, Butler PJ, Evans PR, McMahon HT. BAR domains as sensors of membrane curvature: The amphiphysin BAR structure. Science (New York, NY) 2004;303(5657):495-499.